Cargando…

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin

BACKGROUND: To date, there has been no study that compares the efficacy and safety of warfarin in atrial fibrillation (AF) patients with Evaluated Heartvalves, Rheumatic or Artificial (EHRA) type 2 valvular heart disease (VHD). This study was conducted to determine the optimal INR in these patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Luengsupabul, Sirote, Methavigul, Komsing, Methavigul, Ratikorn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279990/ https://www.ncbi.nlm.nih.gov/pubmed/32528567 http://dx.doi.org/10.1002/joa3.12342

Ejemplares similares

Use of simplified HAS‐BLED score in patients with atrial fibrillation receiving warfarin
por: Methavigul, Komsing, et al.
Publicado: (2019)

Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation
por: Yamkasikorn, Janekij, et al.
Publicado: (2022)

Peguero–Lo Presti criteria modified by body surface area for the electrocardiographic diagnosis of left ventricular hypertrophy in Thai patients
por: Luangphiphat, Wongsakorn, et al.
Publicado: (2021)

Efficacy of R(2)CHA(2)DS(2)-VA score for predicting thromboembolism in Thai patients with non-valvular atrial fibrillation
por: Methavigul, Komsing, et al.
Publicado: (2021)

Revised HAS‐BLED score for bleeding prediction in atrial fibrillation patients with oral anticoagulants
por: Methavigul, Komsing
Publicado: (2022)

Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT(2)R(2) score
por: Methavigul, Komsing, et al.
Publicado: (2023)

Influence of gender on the clinical outcomes of Asian non-valvular atrial fibrillation patients: insights from the prospective multicentre COOL-AF registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOL‐AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2023)

How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?
por: Kim, Jun Hyung, et al.
Publicado: (2009)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study
por: Krittayaphong, Rungroj, et al.
Publicado: (2018)

The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study
por: Ohgushi, Atsushi, et al.
Publicado: (2016)

Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2020)

Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study
por: Al-Najar, Mahasen, et al.
Publicado: (2023)

Optimal INR level for warfarin therapy after mechanical mitral valve replacement
por: Kamthornthanakarn, Itthidet, et al.
Publicado: (2019)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)
por: Smith, Danielle E, et al.
Publicado: (2010)

Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study
por: Kawai, Mayumi, et al.
Publicado: (2019)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Effects of structured patient education on knowledge level and INR control of patients receiving warfarin: Randomized Controlled Trial
por: Baysal, Ebru, et al.
Publicado: (2018)

The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis
por: de Souza Lima Bitar, Yasmin, et al.
Publicado: (2019)

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation
por: Pengo, Vittorio, et al.
Publicado: (2015)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
por: Samaras, Athanasios, et al.
Publicado: (2021)

Age‐dependency of EHRA improvement based on quality of life at diagnosis of atrial fibrillation
por: Theunissen, Luc J. H. J., et al.
Publicado: (2022)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Warfarin/herbal drink interaction: Elevated INR: case report
Publicado: (2021)

A CONTROVERSY: WARFARIN FAILURE IN COVID-19 WITH SUPRATHERAPEUTIC INR
por: Ur Rahman, Saad
Publicado: (2023)

Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease
por: Ahmad, Saad, et al.
Publicado: (2016)

Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study)
por: Dalmau Llorca, M. Rosa, et al.
Publicado: (2021)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vpemo5jpepc3vr27i8o5gt21ct